Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Opus Genetics presented positive clinical and preclinical data at ARVO 2026, showing restoration of cone-mediated vision in pediatric LCA5 patients and early visual acuity gains in BEST1 trials. The data also demonstrated a mutation-independent AAV approach with potential to treat genetically diverse retinal diseases using a single therapy.
Key figures
- Phase Of Trial
- Phase 1/2/3
- Best1 visual acuity improvement
- 12 letters
- Lca5 cone sensitivity improvement
- 30-fold
- Gmp vector no adverse effect level
- established
- Swine model cone function maintenance
- over time
- Swine model visual response restoration
- rod-driven
- Best1 central subfield thickness reduction
- 23%
- Swine model retinal structure preservation
- outer retinal thickness and photoreceptor morphology
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.